Feline mammary carcinoma stem cells are tumorigenic, radioresistant, chemoresistant and defective in activation of the ATM/p53 DNA damage pathway  by Pang, L.Y. et al.
The Veterinary Journal 196 (2013) 414–423Contents lists available at SciVerse ScienceDirect
The Veterinary Journal
journal homepage: www.elsevier .com/ locate / tv j lFeline mammary carcinoma stem cells are tumorigenic, radioresistant,
chemoresistant and defective in activation of the ATM/p53 DNA damage pathway
L.Y. Pang a,⇑, T.M. Blacking a, R.W. Else a, A. Sherman a, H.M. Sang a, B.A. Whitelaw a, T.R. Hupp b, D.J. Argyle b
a The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Edinburgh EH25 9RG, UK
bCancer Research UK Cell Signalling Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK
a r t i c l e i n f oArticle history:
Accepted 13 October 2012
Keywords:
Feline mammary carcinoma
Cancer stem cell
p53
Epithelial–mesenchymal transition1090-0233  2012 Elsevier Ltd.
http://dx.doi.org/10.1016/j.tvjl.2012.10.021
⇑ Corresponding author. Tel.: +44 131 6519164.
E-mail address: lisa.pang@ed.ac.uk (L.Y. Pang).
Open access under CC BYa b s t r a c t
Cancer stem cells were identiﬁed in a feline mammary carcinoma cell line by demonstrating expression
of CD133 and utilising the tumour sphere assay. A population of cells was identiﬁed that had an invasive,
mesenchymal phenotype, expressed markers of pluripotency and enhanced tumour formation in the
NOD-SCID mouse and chick embryo models. This population of feline mammary carcinoma stem cells
was resistant to chemotherapy and radiation, possibly due to aberrant activation of the ATM/p53 DNA
damage pathway. Epithelial–mesenchymal transition was a feature of the invasive phenotype. These data
demonstrate that cancer stem cells are a feature of mammary cancer in cats.
 2012 Elsevier Ltd. Open access under CC BY license. Introduction
Mammary tumours frequently develop in female domestic cats
and are the third most commonly reported cancer in this species
(Hayes and Mooney, 1985). Approximately 80% of these tumours
are malignant, rapidly metastasising and often fatal. Surgery is
the most widely used treatment (Vail and MacEwen, 2000). The
mean age of development of mammary neoplasia in cats is
10–12 years (Zappulli et al., 2005). Cats that are ovariohysterecto-
mised <6 months of age have a reduced risk of developing
mammary tumours when compared to intact females, indicating
that hormones are involved in the pathogenesis of the disease
(Overley et al., 2005). Collectively, this evidence suggests that
feline mammary carcinoma is similar to human breast cancer in
terms of relative age of onset, incidence, histopathology, biological
behaviour and patterns of metastasis.
Accumulating evidence supports the cancer stem cell (CSC)
model of tumorigenesis, whereby a neoplasm can be viewed as
the result of aberrant organogenesis driven by a subpopulation of
CSCs, deﬁned by capacity for self-renewal, differentiation potential
and tumour-initiating ability. It has been proposed that CSCs are
responsible for driving tumour growth and for recurrence after
conventional therapeutic modalities (Pang and Argyle, 2009). Evi-
dence for the existence of CSCs has been found in human acute
myeloid leukaemias (Bonnet and Dick, 1997), breast cancers
(Al-Hajj et al., 2003) and glioblastomas (Singh et al., 2003). In
companion animal medicine, CSCs have been identiﬁed in canine license. osteosarcomas (Wilson et al., 2008), mammary carcinomas (Pang
et al., 2011), gliomas (Stoica et al., 2009) and feline squamous cell
carcinomas (Pang et al., 2012).
Stem-like cells have been isolated from feline mammary carci-
noma (FMC) tissue and characterised in terms of sphere and tu-
mour forming ability (Barbieri et al., 2012). In the present study,
we used a FMC cell line to characterise feline mammary CSCs in
terms of increased expression of speciﬁc stem cell markers, higher
potential for mammosphere formation, invasiveness and resis-
tance to radiation and chemotherapy compared to the bulk tumour
population.Materials and methods
Cell culture and mammosphere formation
FMC cells (Norval et al., 1985) were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS)
and 100 lg/mL streptomycin (Gibco). To assess anchorage independent culture,
FMC cells were plated as single cells and grown as described previously (Pang
et al., 2012).RNA extraction and reverse transcription PCR
Total cellular RNA was extracted using the RNeasy kit (Qiagen) and RNA quality
was determined by measurement of absorbance at 260 nm (A260). Semi-quantita-
tive reverse transcriptase (RT)-PCR analysis of mRNA expression of Oct4, Nanog
and STAT3 was performed as described previously (Pang et al., 2011). Semi-quanti-
tative analysis was carried out using ImageJ.11 See: http://rsbweb.nih.gov/ij/.
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Cells were lysed in in 7 M urea, 0.1 M dithiothreitol (DTT), 0.05% Triton X-100,
25 mM NaCl and 20 mM 4-(2-hydroxyethyl)-1-piperazine ethane sulphonic acid
(HEPES; pH 7.5). Equal amounts of protein were separated by sodium dodecyl sul-
phate–polyacrylamide gel electrophoresis (SDS PAGE), transferred to Hybond-C
nitrocellulose membrane (Amersham Pharmacia Biotech) and hybridised to an
appropriate primary antibody (Table 1), followed by horseradish peroxidase
(HRP)-conjugated secondary antibodies: rabbit anti-mouse immunoglobulin G
(IgG), rabbit anti-goat IgG and porcine anti-rabbit IgG (DakoCytomation; all at
1:1000 dilution). Immunoreactivity was detected by chemiluminescence.
Cell sorting
The Aldeﬂuor Test Kit (Aldagen Stem Cell Technologies) was used to determine
aldehyde dehydrogenase (ALDH) activity. Diethylaminobenzaldehyde (DEAB), a
substrate for class 3 ALDH enzymes and hence a competitive inhibitor of ALDH1,
was used as a negative control.
Flow cytometry with a ﬂuorescence activated cell sorter (FACS Calibur; BD Bio-
sciences) was used to identify a side-population phenotype (SP) of FMC cells able to
efﬂux Hoeschst 33342 dye by ABC transporter activity. FMC cells were resuspended
at 1  106 cells/mL in pre-warmed DMEM with 5 lg/mL Hoechst 33342 (Sigma–Al-
drich), with or without 50 lM verapamil (Sigma–Aldrich), and incubated at 37 C
for 90 min. Cells were washed with ice-cold Hank’s balanced salt solution (HBSS)
and treated with 2 lg/mL propidium iodide (Invitrogen), which was used to gate
viable cells. After excitation at 350 nm, ﬂuorescence was measured at 424/
440 nm and 675 nm for detection of blue and red, respectively.
A CD133 cell isolation kit (Miltenyi Biotec) was used for magnetic cell sorting
(MACS).
Invasion assay
The cell invasion ability of isolated cells was determined using a collagen-based
cell invasion assay kit (QCM, Millipore). Cells were seeded into the upper inserts at
1  105 cells per insert in serum-free DMEM and incubated at 37 C in 5% CO2 for
48 h. Non-invading cells were removed. Cells that migrated through the gel insert
to the lower surface were stained and quantiﬁed by colorimetric measurement at
560 nm.
In vitro assays for tumorigenicity
The sphere forming ability of sorted CD133 and CD133+ cells was determined
as described by Pang et al. (2012). The in vitro proliferation rate of isolated CD133
and CD133+ cells was determined by seeding cells in 60 mm dishes at 4  104 cells
per dish in triplicate. Cell proliferation was monitored 24 and 48 h after plating. Live
cells were quantiﬁed by staining with trypan blue (Invitrogen). Cell viability assays
were performed using CellTiterGlo (Promega). Both assays were normalised to the
number of cells initially seeded.
In vivo assays for tumorigenicity
Non-obese diabetic (NOD)-severe combined immunodeﬁcient (SCID) mice were
purchased from Charles River Laboratories. In vivo experiments were approved by
the Home Ofﬁce, UK (licence number PPL 60/3553, valid until 16 June 2011). Single
cell suspensions of viable FMC cells (1  106: n = 6; 1  104: n = 6) were prepared in
a 100 lL 1:1 mixture of medium (DMEM supplemented with 10% FBS and 100 lg/
mL streptomycin):matrigel (Sigma) and inoculated subcutaneously into the rightTable 1
Primary antibodies used for immunolabelling.
Target kDa Species Clonality Supplier Dilution
b-Actin 42 Mouse Monoclonal Abcam 1:2000
b-Catenin 94 Rabbit Polyclonal Abcam 1:1000
CD133 (k-18) 120 Goat Polyclonal Santa Cruz 1:500
E-cadherin 120 Mouse Monoclonal BD 1:1000
Fibronectin 240 Mouse Monoclonal BD 1:1000
c-H2AX 16 Mouse Monoclonal Abcam 1:1000
MDM2 (4B2) 90 Mouse Monoclonal Moravian
Biotechnology
1:1000
p21 (Ab-1) 21 Mouse Monoclonal Calbiochem 1:1000
p53 (DO12) 53 Mouse Monoclonal Moravian
Biotechnology
1:1000
Phospho-
p53ser15
53 Mouse Monoclonal Cell Signaling 1:1000
Twist 28 Rabbit Polyclonal Santa Cruz 1:500
Vimentin 57 Mouse Monoclonal Abcam 1:500ﬂank of each mouse. Tumour formation was monitored from 1 week after inocula-
tion. After 3 weeks, all mice were euthanased and tumour volume was assessed
using a digital caliper to measure height, width and depth. Tumours were ﬁxed in
10% neutral buffered formalin, then processed routinely for histopathology.
Chick embryo chorioallantoic membrane assay
To examine the in vivo migration potential of FMC stem cells, we utilised the
chick embryo chorioallantoic membrane (CAM) model (Kunzi-Rapp et al., 2001).
Chick embryos were inoculated with ﬂuorescently labelled dissociated mammo-
spheres or parental adherent cells directly onto their CAM at day 7 of development.
Fertilised Isa Brown layer strain chicken eggs were obtained from the Roslin Insti-
tute, Easter Bush, Edinburgh, UK. Embryos from freshly laid eggs were transferred
into large surrogate chicken eggshells (Perry, 1988), sealed and incubated at
37.5 C in 60% relative humidity with turning through 30 for 7 days. Single cell sus-
pensions of adherent cells and mammospheres were labelled with PKH26, a red
ﬂuorescent live cell membrane dye (Sigma–Aldrich); 2  107 single cells were
washed in serum-free media and then incubated with 4 lM PKH26 dye for 5 min
at room temperature. The reaction was stopped by adding an equal volume of ser-
um. Labelled cells were seeded in complete media, then single cell suspensions of
viable cells (1  105: n = 4) were prepared in 25 lL of a 1:1 mixture of serum-free
medium (DMEM):matrigel (Sigma) and inoculated directly onto the CAM. The em-
bryos were resealed and incubated without turning. Tumour growth and location
were determined at 10 days by microscopic evaluation.
Radiation and cytotoxic drug sensitivity
Mammospheres were disaggregated into single cells prior to irradiation in cul-
ture medium (DMEM supplemented with 10% FBS and 100 lg/mL streptomycin)
using a Faxitron cabinet X-ray system 43855D at a central dose rate of 2 Gy/min.
Cells were treated with 1 nM doxorubicin (Adriamycin, Pharmacia/Pﬁzer; catalogue
number 16151), mitoxantrone hydrochloride (Novantrone, Baxter Healthcare; cat-
alogue number 2636B2049) or vincristine sulfate (Oncovin, Hospira; catalogue
number 61703-309-06). All drugs were of pharmaceutical grade and suitable for
injection. All drugs were diluted in medium (DMEM supplemented with 10% FBS
and 100 lg/mL streptomycin) immediately before use. Cytotoxicity was measured
using the CellTiter-Glo Luminescent Cell Viability Assay (Promega), as described
by Pang et al. (2012). Data were averaged and normalised against the average signal
of untreated/vehicle control treated samples.
FMC cells and mammospheres were trypsinised into single cells and seeded at
500 cells/10 cm plate for colony formation assays. The cells were irradiated at 0, 1,
2.5 and 5 Gy in suspension. Plates were incubated at 37 C in a humidiﬁed CO2 incu-
bator until colonies were visible. Growth media was changed once per week. Colo-
nies were ﬁxed by incubating with ice cold methanol for 5 min at room
temperature, then stained with Giemsa (Invitrogen).
Subcellular proteome extraction
The Subcellular Proteome Fractionation Kit (Thermo Scientiﬁc) was used to ex-
tract proteins from mammalian cells according to their subcellular localisation. All
fractions were stored at 70 C and analysed by Western blot analysis (see above).
Statistical analysis
Analysis of variance (ANOVA), Student’s t test and the Mann–Whitney U test
were performed using Minitab. Data are expressed as means ± standard deviation
(SD). The criterion for signiﬁcance was P < 0.05.
Results
Isolation of cells with stem cell features from feline mammary
carcinoma cells
FMC cells formed mammospheres after 7–10 days in culture at
low density (Fig. 1A). These cells were expanded in vitro and
formed mammospheres for 20 subsequent passages. Adherent
FMC cells had a cobblestone-like epithelial appearance (Fig. 1B).
Mammospheres transferred back into adherent conditions at-
tached and grew as monolayers (Fig. 1C).
ALDH activity of FMC cells was measured to assess the presence
and size of a stem cell-like population. A small population of ALDH+
FMC cells was isolated (Fig. 1D–G). The SP fraction was 0.85% of to-
tal cells (Fig. 1H). Incubation in the presence of 100 lM verapamil,
an ABC transporter inhibitor, abolished the SP (Fig. 1I), indicating
that the FMC cell line contains a subpopulation of stem-like cells.
Fig. 1. Isolation and identiﬁcation of putative cancer stem cells showing that mammospheres can be derived from a feline mammary carcinoma cell line. (A) Spherical
colonies derived from parental cells cultured without serum in an anchorage dependent manner. Scale bar = 50 lm. (B) Parental adherent cells. Scale bar = 20 lm. (C)
Mammosphere colony removed from suspension culture and allowed to attach to a substratum. Adherent cells can be seen expanding from the sphere. Scale bar = 50 lm.
Identiﬁcation of aldehyde dehydrogenase 1+ (ALDH1+) and side-population cells from feline mammary carcinoma cells. The percentage of ALDH1+ cells isolated from FSHHigh
and FSHLow populations was 0.81% (D) and 1.24% (F), respectively. Diethylaminobenzaldehyde (DEAB) was used as a negative control (E and G). A Hoechst 33342 dye
exclusion assay on feline mammary carcinoma cells identiﬁed a side-population of 0.85% (H). Incubation with verapamil abolished the side population (I).
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Fig. 2. Characterisation of a subpopulation of CD133+ feline mammary carcinoma cells enriched for spheroid forming ability. A small population of CD133+ cells existing in
feline mammary carcinoma cells were isolated by magnetic cell sorting. (A) CD133+ and CD133 cell fractions were processed and analysed for the expression of CD133
(120 kDa) by Western blot analysis. Single cells sorted for CD133 expression were evaluated for the potential to form spherical colonies in serum-free medium. Spheres
formed from CD133+ cells (B) but not CD133 cells (C). Scale bars = 20 lM. (D) The numbers of the resultant spherical colonies from CD133+ and CD133 cells were counted.
Data are representative of three independent experiments (P = 0.01). CD133 cells have a higher growth potential than CD133+ cells, as illustrated by (E) trypan blue
exclusion assay (P = 0.02) and (F) cell viability assay (P = 0.018). (G) Reverse transcriptase (RT)-PCR analysis of Oct4, Nanog, STAT3 and b-actin gene expression levels. (H)
Quantiﬁcation of RT-PCR results using ImageJ to determine the relative density of the bands compared to b-actin loading controls.
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cells
CD133+ cells (mean ± SD: 0.72 ± 0.25%; 10 replicates) were iso-
lated from FMC cells by MACS. Western blot analysis conﬁrmed
that CD133 expression was restricted to the CD133+ cell popula-
tion (Fig. 2A). CD133+ cells formed more and larger mammo-
spheres (Fig. 2B) than CD133 cells (Fig. 2C) when cultured in
serum-free medium (P = 0.01). In addition, CD133 cells gave rise
to more cells after 48 h than CD133+ cells, as measured by trypan
blue exclusion (P = 0.02, Fig. 2E) and cellular adenosine triphos-
phate (ATP) measured by cell viability assay (P = 0.018, Fig. 2F).
These data indicate that CD133+ cells are more representative of
stem cells than their CD133 counterparts. Using semi-quantita-
tive RT-PCR, mammospheres and CD133+ cells expressed higher
mRNA levels of the embryonic stem cell (ESC)-speciﬁc genesOct4, Nanog and STAT3 compared to adherent cells and CD133
cells, respectively (Fig. 2 G and H).In vivo tumorigenic potential of mammospheres
Single cells were expanded to 1  106 (n = 6) or 1  104 (n = 6)
cells and implanted by subcutaneous injection into the right ﬂanks
of female NOD-SCID mice. Thirteen days after inoculation, dissoci-
ated mammosphere cells initiated growth of more tumours (3/6)
than parental adherent cells (0/6) with the implantation of
1  104 (n = 6) cells (Fig. 3A). Three weeks after inoculation, tu-
mours derived from dissociated mammospheres were signiﬁcantly
larger than those from parental adherent cells (104 cells: 4.7-fold
increased size, P = 0.03; 106 cells: 10-fold increased size,
P = 0.005; Fig. 3B and C). However, despite differences in size, both
Fig. 3. Mammospheres are enriched for high tumorigenicity in vivo. Dissociated mammospheres and adherent cells were injected SC into NOD-SCID mice. The number of
mice with a tumour was tabulated (A) and representative images of tumours 3 weeks after inoculation are shown (B). (C) Tumour volumes generated by spheres and adherent
cells were measured and recorded 3 weeks after inoculation: 104: P < 0.04; 106: P < 0.001. (D) Haematoxylin and eosin staining of histological sections of representative
xenograft tumour sections. Scale bar = 50 lm.
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qualitative differences (Fig. 3D).Invasiveness of mammospheres and CD133+ cells
Cells derived from mammospheres were signiﬁcantly more
invasive than parental adherent cells both with (P < 0.005) and
without (P < 0.001) FBS (Fig. 4A and B). Similar results were ob-
tained with matched CD133+ and CD133 cells (see Appendix A:
Supplementary Fig. 1).
Western blot analysis demonstrated that mammospheres and
CD133+ cells exhibited a shift towards mesenchymal phenotypes,
including down-regulation of the epithelial markers E-cadherin
and b-catenin, and up-regulation of the mesenchymal markers
ﬁbronectin and vimentin (Fig. 4C).
Tumours formed in 100% of chick embryo CAMs inoculated with
dissociated mammospheres, but not in CAMs inoculated with
parental adherent cells (Fig. 4D). Using ﬂuorescence microscopy,
tumours derived from mammospheres were brightly ﬂuorescent
and had radiated out from the site of inoculation, invading the sur-
rounding blood vessels of the CAM. In contrast, adherent cells were
weakly ﬂuorescent and were localised to the initial site of inocula-
tion (Fig. 4D).In vitro resistance of mammospheres and CD133+ cells to irradiation
and chemotherapeutic agents
In the cytotoxicity assay, CD133+ FMC cells were more resistant
to doxorubicin (Fig. 5A; P = 0.026) and mitoxantrone (Fig. 5B;
P = 0.029) than CD133 cells. Similarly, mammospheres were more
resistant than parental adherent cells to 1 nM doxorubicin
(P < 0.003), 1 nM mitoxantrone (P < 0.001) and 1 nM vincristine
(P < 0.001) (Fig. 5C).
Adherent parental cells exhibited a dose dependent decrease in
viability with increasing doses of irradiation, whereas mammo-
sphere viability was unaffected until a dose of 5 Gy was reached
(Fig. 5D). This was conﬁrmed by clonogenic analysis (Fig. 5E,
P < 0.009).Activation of DNA damage pathways in feline mammary carcinoma
cells
In response to doxorubicin, adherent cells showed a transient
increase in phosphorylation of p53-serine15, an ATM target that
is associated with activation of p53 transcriptional activity (Kastan
et al., 1991), and of the p53 transcriptional target p21WAF1/Cip1 at 2 h
post-treatment (Fig. 6A).
Fig. 4. Putative cancer stem cells show an increased in vitro and in vivo invasive potential and exhibit mesenchymal phenotypes. (A) Examination of invasive ability of sorted
CD133+ cells utilising a collagen-based cell invasion assay. FBS, fetal bovine serum. (B) Quantiﬁcation of invading cells. P < 0.001; P < 0.005; OD560, Optical density at
560 nm. (C) Western blot analysis of E-cadherin, ﬁbronectin, vimentin and b-catenin, with b-actin as a loading control. (D) Evaluation of in vivo tumorigenesis and
invasiveness in a chick embryo model. Bright ﬁeld image of the chorioallantoic membrane (CAM) 3 days after inoculation with feline mammary carcinoma cells (left panel)
and ﬂuorescence image of tumour cells 3 days after inoculation (right panel). Red arrows indicate opaque plaques representative of tumour growth.
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strand breaks (Rogakou et al., 1998), similarly increased 2 h
post-treatment in adherent cells (Fig. 6A), whereas in mammo-
spheres treated with doxorubicin cH2AX could not be detected
and phosphorylation of p53-serine15 was delayed until 6 h
post-treatment. Similar results were obtained in response to irra-
diation (Fig. 6B).
In untreated parental adherent cells, p53 protein was detected
at a low level and was associated with the cytosolic and nuclear
fractions, whereas in untreated mammospheres p53 protein levels
were relatively high and were predominantly associated with
membranes and, to a lesser extent, the nucleus (Fig. 6C). Upon
DNA damage, the p53 protein levels in adherent cells increased
in both the cytoplasmic and nuclear fractions, whereas in mammo-
spheres p53 protein levels and subcellular localisation remain un-
changed (Fig. 6C).Discussion
The concept of CSCs is still evolving, but data implicating these
cells in tumour maintenance and resistance to therapeutic agents
suggest that there is value in targetting CSCs in combination with
conventional therapies (Pang and Argyle, 2009). In this study, CSCs
were isolated from a feline mammary carcinoma cell line by mam-
mosphere formation. The ability of mammospheres to grow in
anchorage-independent conditions and to form three-dimensional
spherical structures in serum-free medium is recognised as a stem
cell characteristic (Singh et al., 2003). The expression of ALDH1 by
mammospheres correlates with the self-renewal properties of CSCs
(Ginestier et al., 2007). We also isolated a CD133+ population of
FMCs; previous studies have demonstrated that human CSCs can
be enriched through the use of cell surface markers such as
Fig. 5. Mammospheres and CD133+ cells are resistant to conventional therapeutic agents. CD133+ and CD133 cells were treated with increasing concentrations of (A)
doxorubicin (P = 0.026) or (B) mitoxantrone (P = 0.029) and cell viability was assayed 48 h post-treatment. Mammospheres and adherent cells were treated with 1 nM
vincristine (#P < 0.003), 1 nM mitoxantrone (##P < 0.001) or 1 nM doxorubicin (###P < 0.001) and cell viability relative to untreated controls (0 nM) was assayed 48 h after
treatment (C). Mammospheres and adherent cells were treated with increasing doses of c-radiation and assayed for (D) cell viability (P = 0.029; P = 0.015; P = 0.001) and
(E) colony formation ability (#P = 0.009; ##P = 0.003; ###P = 0.089).
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Hermann et al., 2007; O’Brien et al., 2007).
Previously, we demonstrated that expression of CD44 in feline
cancer cells is cell cycle dependent (Blacking et al., 2011) andtherefore it is not appropriate to utilise CD44 as a CSC marker in
this species. Furthermore, available antibodies against CD24 dem-
onstrate inconsistent cross-reactivity in the feline system (data not
shown). Putative tumour initiating cells previously have been
Fig. 6. Feline cancer stem cells lack activation of the p53 DNA damage pathway in response to doxorubicin and ionising radiation. (A) Dissociated mammospheres and
parental adherent cells were treated with 10 lM doxorubicin or dimethyl sulfoxide (DMSO), cells were harvested over the indicated time course and expression of p53
pathway related proteins was assessed. (B) Dissociated mammospheres and parental adherent cells were treated with 5 Gy ionising radiation, cells were harvested over the
indicated time course and expression of proteins related to the p53 pathway was assessed. Dissociated mammospheres and adherent cells were incubated with 2.5 lM
doxorubicin (Dox) or DMSO. Proteins were extracted according to their subcellular localisation: F1, cytosolic; F2, membranes/organelles; F3, nucleus; F4, nucleus; F5,
cytoskeleton. Proteins from each fraction were resolved by SDS–PAGE and analysed by immunoblotting for p53; 30 lg was loaded per lane. Coomassie (CM) staining
conﬁrmed that protein expression proﬁles from each fraction were distinct; 5 lg was loaded per lane (C).
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nog and STAT3, which are important for self-renewal, proliferation,
and fate determining properties of stem cells (Wilson et al., 2008).
In the present study, we showed that putative FMC CSCs, repre-
sented by CD133+ cells, express higher levels of ESC-speciﬁc genes.
STAT3 is persistently activated in a range of tumours and it is not
surprising that STAT3 expression is also detectable in adherent
and CD133 cells. Signiﬁcantly, in xenograft mouse models we
demonstrated that dissociated mammospheres can initiate tumour
development in vivo better than parental adherent cells.
CSCs also may be responsible for mediating tumour metastasis.
Recent evidence indicates that the epithelial–mesenchymal transi-
tion (EMT) pathway drives tumour invasion. EMT is a morphoge-netic process in which cells lose their epithelial characteristics
and gain mesenchymal properties (Cervantes-Arias et al., 2012).
In the present study, we showed that CSCs shift towards a mesen-
chymal phenotype in comparison with parental cells. Using the
chick embryo model, we also showed that feline CSCs are capable
of invading the capillary system of the CAM. Further studies will be
needed to determine whether these cells are capable of initiating
and maintaining tumour growth at a distant site.
A proposed driver of tumour metastasis is the EMT pathway.
Recent evidence indicates that in vitro induction of EMT in
immortalised human mammary epithelial cells is sufﬁcient to gen-
erate mesenchymal cells with properties of stem cells (Mani et al.,
2008). Therefore, the EMT pathway may be sufﬁcient both to
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ties, which permits tumour establishment at a distant site. In our
feline model, we showed that CSCs are inherently more invasive
than parental cells, which is indicative of a mesenchymal pheno-
type. These data substantiate the role of EMT in invasiveness and
metastatic dissemination; the ability to isolate metastatic CSCs
from cell lines should facilitate studies of the molecular mecha-
nisms by which CSCs mediate tumour metastasis.
An emerging characteristic of CSCs is their resistance to conven-
tional therapeutic agents. The molecular mechanisms underlying
the intrinsic resistance of CSCs to conventional therapies are still
undeﬁned. In the feline model system, we investigated the ATM-
p53 DNA damage pathway. Human and mouse ESCs lack the cell
cycle G1/S checkpoint and fail to undergo cellular senescence after
DNA damage, which is effective in somatic cells (Aladjem et al.,
1998). Classically, p53 protects the genome from accumulating ge-
netic mutations by enabling faithful repair of DNA damage or by
elimination of cells with excessive damage (Hupp et al., 2000).
However, p53 is emerging as a major player in stem cell biology
and has been implicated in suppression of pluripotency and cellu-
lar differentiation via suppression of Nanog (Zhao and Xu, 2010).
In the present study, we compared the p53 response of feline
mammospheres to adherent cells in response to doxorubicin.
Adherent cells showed a rapid response to doxorubicin treatment,
whereas in mammospheres there was a delay in activation of p53.
Our data indicate that the mechanism of ATM/p53 pathway inacti-
vation is potentially due to mis-localisation of p53. We propose
that, in the adherent cells, the rapid response of the p53 pathway
is primarily to engage the G1/S checkpoint, whereas in mammo-
spheres the aberrant kinetics of p53 activation and lack of phos-
phorylation of H2AX may indicate an alternative p53 response,
such as induction of differentiation into other cell types that can
undergo efﬁcient p53-dependent cell cycle arrest or apoptosis.
We also observed a higher basal level of p21WAF1/Cip1 in mam-
mospheres compared to adherent cells. In response to DNA dam-
age, p21WAF1/Cip1 mediates G1 arrest (El-Deiry et al., 1994).
However, p21WAF1/Cip1 has a dual role in stem cell regulation, i.e.
to limit self-renewal and to inhibit differentiation (Topley et al.,
1999; Cheng et al., 2000). In this context, our data may indicate
that the high basal level of p21WAF1/Cip1 observed in the putative
CSC population may inhibit differentiation and maintain the size
and self-renewal potential of the CSC pool. The implications of clas-
sical DNA damage response proteins having additional roles in
stem cell biology warrant further investigation.Conclusions
In this study, a FMC cell line was used to characterise feline
mammary CSCs through expression of speciﬁc stem cell markers,
higher potential for mammosphere formation, invasiveness and
resistance to radiation and chemotherapy compared to the bulk tu-
mour population. Similar to human breast cancer models, we were
able to isolate a small population of cells with stem cell properties
from a FMC cell line. Feline CSCs are capable of initiating tumour
growth in the NOD-SCID mouse and chick embryo models. Feline
CSCs are more invasive than other FMC cell line populations and
display attributes of a mesenchymal cell state, which may enhance
invasive capacity. These cells are also chemoresistant and
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